Claims
- 1. A hetero cyclic compound of the formula (I) whereinone of R1, R2 and R5 is hydroxy, carboxy, alkoxycarbonyl, a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, or alkyl or alkenyl substituted by hydroxy, carboxy, sulfonic acid, phosphoric acid group, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy; either R3 or R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NER8 wherein R8 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy; R6 is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl, provided that when one of R1 and R2 is alkoxy the other should not be alkyl substituted by a group of the formula —NR9R10; or a pharmaceutically acceptable salt thereof.
- 2. The heterocyclic compound of claim 1, wherein, in the formula (I), one of R1, R2 and R1 is alkyl or alkenyl substituted by hydroxy, carboxy. sulfonic acid, phosphoric acid group, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy, or a pharmaceutically acceptable salt thereof.
- 3. The heterocyclic derivative of claim 3, which is represented by the formula (IIb) wherein R1b and R3b are each indedently hydrogen atom, lower alkyl or lower alkoxy, R2b bis alkyl substituted by hydroxy, carboxy or alkoxycarbonyl, R4b is a group of the formula —NHCOR7b wherein R7b is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8b wherein R8b is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, and R6b is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl, or a pharmaceutically acceptable salt thereof.
- 4. The heterocyclic derivative of claim 3, wherein, in the formula (IIb), R1b and R3b are each independently lower alkyl or lower alkoxy, R2b is alkyl substituted by hydroxy, carboxy or alkoxycarbonyl, R4b is a group of the formula —NHCOR7b wherein R7b is alkyl, cycloalkylalkyl, arylalkyl or a group of the formula —NHR8b wherein R8b is alkyl, and R6b is alkyl, alkoxyalkyl, alkylthioalkyl or cycloalkylalkyl, or a pharmaceutically acceptable salt thereof.
- 5. The heterocyclic compound of claim 4, wherein, in the formula (IIb), R1b and R3b are each independently lower alkyl, R2b is alkyl substituted by hydroxy or carboxy, R4b is a group of the formula —NHCOR7b wherein R7b is alkyl, and R6b is alkyl, or a pharmaceutically acceptable salt thereof.
- 6. The heterocyclic compound of claim 5, wherein the compound of the formula (IIb) is selected from the group consisting of:(1) N-(1-hexyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (2) N-(1-heptyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (3) N-(1-octyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (4) N-(1-nonyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (5) N-(1-decyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (6) N-(1-hexyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (7) N-(1-heptyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (8) N-(1-octyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (9) N-(1-nonyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, (10) N-(1-decyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, or a pharmaceutically acceptable salt thereof.
- 7. The heterocyclic compound of claim 1, wherein, in the formula (I), one of R1, R2 and R5 is hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy,or a pharmaceutically acceptable salt thereof.
- 8. A pharmaceutical composition comprising an effective amount of a heterocyclic compound of any one of claims 1, 2, 3, 4, 5, 6, or 7 or a pharmaceutically acceptable salt thereof.
- 9. A method for inhibiting acyl-CoA:cholesterol acyltransferase in a patient in need of same which comprises administering to said patient the composition of claim 8.
- 10. A method for inhibiting lipoperoxidation in a patient in need of same which comprises administering to said patient the composition of claim 8.
- 11. The pharmaceutical composition according to claim 8 for the inhibition of acyl-CoA: cholesterol acyltransferase which farther comprises a pharmaceutically acceptable carrier.
- 12. The pharmaceutical composition according to claim 8 for the inhibition of lipoperoxidation which further comprises a pharmaceutically acceptable carrier.
- 13. A method of inhibiting acyl-CoA: cholesterol acyltransferase in a patient in need of same which comprises administering to said patient the composition of claim 11.
- 14. A method for inhibiting lipoperoxidation in a patient in need of same which comprises administering to said patient the composition of claim 12.
Priority Claims (3)
Number |
Date |
Country |
Kind |
7-259082 |
Oct 1995 |
JP |
|
8-058018 |
Mar 1996 |
JP |
|
8-194331 |
Jul 1996 |
JP |
|
TECHNICAL FIELD
This is a divisional of Ser. No. 09/051,202, filed Apr. 3, 1998, now U.S. Pat. No. 6,063,806, which is a 371 of PCT/JP96/02852, filed Sep. 30, 1996.
US Referenced Citations (5)
Foreign Referenced Citations (15)
Number |
Date |
Country |
0 622 356 |
Nov 1994 |
EP |
0 708 091 |
Apr 1996 |
EP |
0 793 140 |
Sep 1997 |
EP |
2-117651 |
May 1990 |
JP |
3-7259 |
Jan 1991 |
JP |
3-148247 |
Jun 1991 |
JP |
4-66568 |
Mar 1992 |
JP |
4-234839 |
Aug 1992 |
JP |
4-327564 |
Nov 1992 |
JP |
5-32666 |
Feb 1993 |
JP |
5-97802 |
Apr 1993 |
JP |
5-140102 |
Jun 1993 |
JP |
8-92210 |
Apr 1996 |
JP |
8-208602 |
Aug 1996 |
JP |
WO9609287 |
Mar 1996 |
WO |
Non-Patent Literature Citations (4)
Entry |
K. Yee et al., J. Med. Chem. , 33(9), 2437-2451 (1990). |
V. Matassa et al., J. Med. Chem., 33(6), 1781-1790 (1990). |
F. Brown et al., J. Med. Chem., 33(6), 1771-1781 (1990). |
V. DeVries et al., J. Med. Chem., 29, 1131-1133 (1986). |